Therapeutics News

NEW YORK – Marc Bloomenstein, OD, said he uses Kala’s new Inveltys (loteprednol etabonate ophthalmic suspension 1%) in both cataract and refractive surgery patients.

NEW ORLEANS – New drug delivery technologies will assist clinicians in treating noncompliant glaucoma patients, Ike K. Ahmed, MD, said here at SECO.

Maynard L. Pohl, OD, FAAO: My personal clinical mission in the perioperative care I provide is to strive for excellence in helping to meet each patient’s visual expectations after surgery. Additional measures taken to enable a patient experience that has high value means maintaining a superior quality while reducing cost to the patient. Certainly, this fundamental should apply when it comes to arranging a patient’s cataract postoperative medications.

NEW ORLEANS – It is time to change the glaucoma treatment paradigm, Ike K. Ahmed, MD, said here at SECO.

NEW ORLEANS – A multitude of treatments options in development for the ocular surface, retina and glaucoma have the potential to greatly improve patient outcomes and quality of life, Chris Wroten, OD, DiplABO, said here at SECO.

NEW ORLEANS – A panel here at the Ophthalmic Innovation Summit, held during SECO, recognized the dramatic advances made in the field of glaucoma technology and therapeutics but also recognized the challenges with implementation.

NEW ORLEANS – Participants on an industry panel here at the Ophthalmic Innovation Summit held during SECO agreed that optometry’s involvement with and value to their businesses is growing.

It’s a scenario that plays out all too often. You consult with a complex patient, perhaps at the request of a colleague or primary care physician. After listening intently and a careful examination, you provide a well-orchestrated management plan, the cornerstone of which is a specific therapeutic agent. The patient is in complete agreement with your recommendation, thanks you and heads to the pharmacy for their medication.

Optometrists have the opportunity to be “heroes” by using knowledge and technology to combat surface inflammation, loss of homeostasis, decreased tear production and meibomian gland disease.

“Prior authorizations are here to stay,” Jeffrey S. Williams Jr., OD, Dipl ABO, told Primary Care Optometry News. Optometrists must learn how to navigate prior authorizations in order for their patients to receive the branded medications they are prescribed, he said.